Benitec Biopharma Receives FDA Clearance of IND for BB-301
By Chris Wack
Benitec Biopharma said Monday the U.S. Food and Drug Administration cleared its Investigational New Drug application for BB-301, a silence-and-replace gene therapy for the treatment of oculopharyngeal muscular dystrophy-related dysphagia.
The company said subjects from Benitec's ongoing study will be eligible for rollover into the Phase 1b/2a clinical study of BB-301 for the treatment of OPMD-related dysphagia after six months of baseline data collection.
Following a one-day dosing procedure for BB-301, each study subject will be evaluated for radiographic and clinical outcome measures, including quantitative radiographic swallowing studies to facilitate objective assessments of swallowing safety, swallowing efficiency, and functional performance of the pharyngeal muscles underlying the OPMD-related dysphagia.
Benetic said there are 13 subjects enrolled into the study, with each subject having the potential to rollover onto the Phase 1b/2a clinical dosing study for BB-301. Interim safety and efficacy data is expected to become available from the BB-301 Phase 1b/2a study every 90 days following the dosing of each subject.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
June 26, 2023 08:37 ET (12:37 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Markets Brief: AI Leaders Excel in Earnings Season
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth